Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma

NCT01033240 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01033240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01033240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
July 9, 2010
Completion date
September 9, 2013
Enrollment
172 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, hepatic cancer, liver cancer, liver neoplasms